-
β-Elemene: From Adipogenesis to Assay Strategy
2026-08-20
β-Elemene is a mechanistically rich tool for studying adipogenesis, insulin resistance, and AMPK signaling. This guide translates recent 3T3-L1 evidence into an assay strategy that distinguishes pathway modulation from nonspecific cytotoxicity and clarifies limits for neuroprotection and cancer research.
-
U 46619: A TP-Receptor Assay Strategy
2026-08-19
U 46619, also called 11,9 epoxymethano-prostaglandin H2, provides a concentration-resolved way to study TP-receptor signaling across platelets and vascular models. This article connects its pharmacology with assay design, translational interpretation, and the phase 3 vernakalant trial without conflating platelet agonism with antiarrhythmic efficacy.
-
Relative Viability vs Fractional Cell Killing in Cancer
2026-08-19
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent dimensions of in vitro drug response. The work provides a practical framework for interpreting anticancer screening data, selecting complementary endpoints, and avoiding conclusions based on a single viability measurement.
-
Vernakalant for Rapid Atrial Fibrillation Conversion
2026-08-18
This phase 3 randomized trial found that intravenous vernakalant rapidly converted short-duration atrial fibrillation to sinus rhythm more often than placebo, with a median conversion time of 11 minutes. Its atrium-focused electrophysiological profile and duration-stratified design provide a useful framework for evaluating rapid pharmacological cardioversion, while the reported serious adverse events emphasize the need for monitored use.
-
Bufalin: Mechanisms and Cancer Research Evidence
2026-08-18
Bufalin is a cardiotonic steroid with documented preclinical activity in apoptosis, differentiation, and cancer biology. Recent evidence identifies STK33 as a Bufalin-binding and degradation-sensitive target in triple-negative breast cancer research, while product information describes additional estrogen receptor alpha and CPT1A applications.
-
Anlotinib hydrochloride in Angiogenesis Assays
2026-08-17
Learn how Anlotinib hydrochloride (SKU C8688) can improve interpretation of endothelial migration, tube formation, viability, and proliferation experiments. This scenario-based guide connects receptor-level potency with practical controls, dose selection, and evidence-based product evaluation.
-
PDHA1 Acetylation and Cuproptosis in CRPC
2026-08-17
This 2026 study identifies PDHA1-dependent acetyl-CoA and H3K27ac signaling as a mechanism that suppresses cuproptosis and weakens enzalutamide response in castration-resistant prostate cancer. Its findings connect mitochondrial carbon metabolism, antioxidant capacity, copper handling, and anti-androgen resistance, suggesting that PDHA1 inhibition could restore drug sensitivity in refractory disease.
-
Metabolic Readouts of Sorafenib Resistance
2026-08-16
How HNF4A-AS1, lipid remodeling, and ferroptosis research can be translated into a disciplined metabolic phenotyping workflow using fluorescence-based glucose uptake measurements.
-
TGEV M–HSC70 Interaction Drives Viral Internalization
2026-08-15
Ji et al. identify HSC70 as a host factor that connects the TGEV membrane protein with clathrin-mediated endocytosis during early infection. The study expands the role of coronavirus M protein beyond assembly and budding, while highlighting HSC70 ATPase activity and M–HSC70 binding as mechanistic points for further investigation.
-
BIBR 1532: Telomerase Assay Guide
2026-08-14
A scenario-based guide to using BIBR 1532 for telomerase activity assays, cancer cell proliferation inhibition, and apoptosis interpretation. It explains solvent compatibility, protocol controls, literature boundaries, and vendor-selection considerations for SKU A1945.
-
DAPI Solution (1 mg/mL): Reliable Cell Assays
2026-08-14
Learn how DAPI and DAPI Solution (1 mg/mL), SKU K2401, can strengthen nuclear visualization, membrane-compromise measurements, and flow cytometry DNA staining in cell-based assays. This scenario-driven guide separates validated product specifications from workflow recommendations and explains how to interpret DAPI data alongside mechanistic cancer research.
-
ω-Agatoxin IVA TFA: An Assay-Logic Guide
2026-08-13
ω-Agatoxin IVA TFA is more than a P/Q-type channel blocker: it is a precision tool for separating Cav2.1-dependent current, neurotransmitter release, and downstream neuroprotection. This guide translates its P-versus-Q pharmacology into practical neuronal calcium current recording, synaptic transmission research, and epilepsy study decisions.
-
Asunaprevir: From Protease Mechanism to Translation
2026-08-13
Asunaprevir (BMS-650032) illustrates how a highly selective HCV NS3/4A protease inhibitor can be evaluated as more than an enzyme assay hit. This thought-leadership analysis connects molecular mechanism, genotype-aware validation, hepatotropic exposure, translational modeling, and lessons from chromatin-focused drug discovery.
-
Lisinopril dihydrate: Assay Logic in RAS Models
2026-08-12
Lisinopril dihydrate is a long-acting ACE inhibitor for mechanistic renin–angiotensin system research. This guide connects biochemical potency, aminopeptidase selectivity, formulation control, and cardiovascular or renal disease models.
-
Pravastatin sodium Research Workflows
2026-08-12
Pravastatin sodium enables mechanism-led cholesterol biosynthesis inhibition, LDL handling studies, and transporter-aware hepatocyte workflows. This practical guide connects dose selection, cytotoxicity controls, macrophage assays, and botanical interaction testing for more interpretable results.